JP2017523972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523972A5 JP2017523972A5 JP2017504815A JP2017504815A JP2017523972A5 JP 2017523972 A5 JP2017523972 A5 JP 2017523972A5 JP 2017504815 A JP2017504815 A JP 2017504815A JP 2017504815 A JP2017504815 A JP 2017504815A JP 2017523972 A5 JP2017523972 A5 JP 2017523972A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- benzamide
- hydroxy
- piperidylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1H-tetrazolyl Chemical group 0.000 claims description 185
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 81
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 17
- POVNVOVBMZEQNF-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cycloheptyl(methyl)sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(C)C1CCCCCC1)(=O)=O)=O)O POVNVOVBMZEQNF-UHFFFAOYSA-N 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 7
- AFFKBANIVDVAJZ-UHFFFAOYSA-N 2-(3-piperidin-1-ylsulfonylphenyl)-1H-benzimidazol-4-ol Chemical compound N1(CCCCC1)S(=O)(=O)C=1C=C(C=CC=1)C=1NC2=C(N=1)C=CC=C2O AFFKBANIVDVAJZ-UHFFFAOYSA-N 0.000 claims description 6
- AKNIMNRBFJJRHU-UHFFFAOYSA-N 2-(3-piperidin-1-ylsulfonylphenyl)benzotriazole Chemical compound N1(CCCCC1)S(=O)(=O)C=1C=C(C=CC=1)N1N=C2C(=N1)C=CC=C2 AKNIMNRBFJJRHU-UHFFFAOYSA-N 0.000 claims description 6
- PLYJLKUDUKDBBL-UHFFFAOYSA-N 2-[[3-[(5-chloro-2-hydroxyphenyl)carbamoyl]phenyl]sulfonyl-cyclohexylamino]acetic acid Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C=1C=C(C=CC=1)S(=O)(=O)N(CC(=O)O)C1CCCCC1)O PLYJLKUDUKDBBL-UHFFFAOYSA-N 0.000 claims description 6
- YFIYZXAOWRTBKF-UHFFFAOYSA-N 3-(1,3-benzoxazol-2-yl)-N-cyclohexyl-N-methylbenzenesulfonamide Chemical compound O1C(=NC2=C1C=CC=C2)C=1C=C(C=CC=1)S(=O)(=O)N(C)C1CCCCC1 YFIYZXAOWRTBKF-UHFFFAOYSA-N 0.000 claims description 6
- FLMVZQMFGDPDRX-UHFFFAOYSA-N 3-(1-adamantylsulfamoyl)-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound C12(CC3CC(CC(C1)C3)C2)NS(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC(=C2)Cl)O)C=CC=1 FLMVZQMFGDPDRX-UHFFFAOYSA-N 0.000 claims description 6
- PLLWPDNWVBCYIJ-UHFFFAOYSA-N 3-(4-benzylpiperazin-1-yl)sulfonyl-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound C(C1=CC=CC=C1)N1CCN(CC1)S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC(=C2)Cl)O)C=CC=1 PLLWPDNWVBCYIJ-UHFFFAOYSA-N 0.000 claims description 6
- WAESAKIHRIQDQM-UHFFFAOYSA-N 3-(5-chloro-1,3-benzoxazol-2-yl)-N-cyclohexyl-N-(3-hydroxypropyl)benzenesulfonamide Chemical compound OCCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(O1)C=CC(Cl)=C2 WAESAKIHRIQDQM-UHFFFAOYSA-N 0.000 claims description 6
- ZHECZGVEWDLDSU-UHFFFAOYSA-N 3-(5-chloro-1,3-benzoxazol-2-yl)-N-cyclohexyl-N-[3-(dimethylamino)propyl]benzenesulfonamide Chemical compound CN(C)CCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(O1)C=CC(Cl)=C2 ZHECZGVEWDLDSU-UHFFFAOYSA-N 0.000 claims description 6
- DBERYRVHZRNFCN-UHFFFAOYSA-N 3-(azepan-1-ylsulfonyl)-n-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCCCCC2)=C1 DBERYRVHZRNFCN-UHFFFAOYSA-N 0.000 claims description 6
- XFWXOLQIOVBGEM-UHFFFAOYSA-N 3-[2-aminoethyl(cyclohexyl)sulfamoyl]-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound NCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC(=C2)Cl)O)C=CC=1)C1CCCCC1 XFWXOLQIOVBGEM-UHFFFAOYSA-N 0.000 claims description 6
- HRXKUHHUDOMZHG-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(2-hydroxy-3-methoxyphenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C(=CC=C2)OC)O)C=CC=1)C1CCCCC1 HRXKUHHUDOMZHG-UHFFFAOYSA-N 0.000 claims description 6
- WBIMANPFRLSCOU-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(2-hydroxyphenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC=C2)O)C=CC=1)C1CCCCC1 WBIMANPFRLSCOU-UHFFFAOYSA-N 0.000 claims description 6
- KCTPFWQJXCELJR-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(2-methoxyphenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC=C2)OC)C=CC=1)C1CCCCC1 KCTPFWQJXCELJR-UHFFFAOYSA-N 0.000 claims description 6
- QTKXLZCQXKKIJL-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(4,5-dichloro-2-hydroxyphenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=C(C(=C2)Cl)Cl)O)C=CC=1)C1CCCCC1 QTKXLZCQXKKIJL-UHFFFAOYSA-N 0.000 claims description 6
- VILVXXZSYPCCAV-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC(=C2)Cl)O)C=CC=1)C1CCCCC1 VILVXXZSYPCCAV-UHFFFAOYSA-N 0.000 claims description 6
- IRHFGYOUFPRAFX-UHFFFAOYSA-N 3-[4-aminobutyl(cyclohexyl)sulfamoyl]-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound NCCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=C(C=CC(=C2)Cl)O)C=CC=1)C1CCCCC1 IRHFGYOUFPRAFX-UHFFFAOYSA-N 0.000 claims description 6
- HDHCWTDUGXNEHU-UHFFFAOYSA-N 3-[benzyl(cyclohexyl)sulfamoyl]-N-(5-chloro-2-hydroxyphenyl)benzamide Chemical compound OC1=C(NC(=O)C2=CC(=CC=C2)S(=O)(=O)N(CC2=CC=CC=C2)C2CCCCC2)C=C(Cl)C=C1 HDHCWTDUGXNEHU-UHFFFAOYSA-N 0.000 claims description 6
- SAGRENOEYPVVJS-UHFFFAOYSA-N 4-[[3-[(5-chloro-2-hydroxyphenyl)carbamoyl]phenyl]sulfonyl-cyclohexylamino]butanoic acid Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C=1C=C(C=CC=1)S(=O)(=O)N(CCCC(=O)O)C1CCCCC1)O SAGRENOEYPVVJS-UHFFFAOYSA-N 0.000 claims description 6
- ONBQXUHKQAJMRY-UHFFFAOYSA-N 4-chloro-2-[(3-piperidin-1-ylsulfonylbenzoyl)amino]benzoic acid Chemical compound ClC1=CC(=C(C(=O)O)C=C1)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1)=O ONBQXUHKQAJMRY-UHFFFAOYSA-N 0.000 claims description 6
- ISLDVUKPWJCSNU-UHFFFAOYSA-N 4-chloro-2-[2-(3-piperidin-1-ylsulfonylphenyl)-1H-imidazol-5-yl]phenol Chemical compound ClC1=CC(=C(C=C1)O)C1=CN=C(N1)C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 ISLDVUKPWJCSNU-UHFFFAOYSA-N 0.000 claims description 6
- ASERCCCTJAWTRV-UHFFFAOYSA-N 4-chloro-2-[3-(3-piperidin-1-ylsulfonylphenyl)-1H-1,2,4-triazol-5-yl]phenol Chemical compound OC1=C(C=C(Cl)C=C1)C1=NC(=NN1)C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 ASERCCCTJAWTRV-UHFFFAOYSA-N 0.000 claims description 6
- VCXMHZOOQPCNKP-UHFFFAOYSA-N 4-chloro-2-[4-(3-piperidin-1-ylsulfonylphenyl)pyrimidin-2-yl]phenol Chemical compound ClC1=CC(=C(C=C1)O)C1=NC=CC(=N1)C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 VCXMHZOOQPCNKP-UHFFFAOYSA-N 0.000 claims description 6
- VLKAAAOFELKTSN-UHFFFAOYSA-N 5,7-dichloro-2-(3-piperidin-1-ylsulfonylphenyl)-3H-benzimidazol-4-ol Chemical compound ClC1=C(C2=C(N=C(N2)C2=CC(=CC=C2)S(=O)(=O)N2CCCCC2)C(=C1)Cl)O VLKAAAOFELKTSN-UHFFFAOYSA-N 0.000 claims description 6
- NGUVSIWCEOPZSI-UHFFFAOYSA-N 5-chloro-2-(3-piperidin-1-ylsulfonylphenyl)-1,3-benzoxazole Chemical compound ClC1=CC2=C(OC(=N2)C2=CC(=CC=C2)S(=O)(=O)N2CCCCC2)C=C1 NGUVSIWCEOPZSI-UHFFFAOYSA-N 0.000 claims description 6
- IJELLJZOWAAJBK-UHFFFAOYSA-N 5-chloro-3-(3-piperidin-1-ylsulfonylbenzoyl)-1H-benzimidazol-2-one Chemical compound ClC1=CC2=C(NC(N2C(C2=CC(=CC=C2)S(=O)(=O)N2CCCCC2)=O)=O)C=C1 IJELLJZOWAAJBK-UHFFFAOYSA-N 0.000 claims description 6
- ZDRWADHUPHQFHN-UHFFFAOYSA-N 5-chloro-N-(3-piperidin-1-ylsulfonylphenyl)-1H-indazol-3-amine Chemical compound ClC=1C=C2C(=NNC2=CC=1)NC1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 ZDRWADHUPHQFHN-UHFFFAOYSA-N 0.000 claims description 6
- BCKFSWAOFTYFDC-UHFFFAOYSA-N 7-chloro-2-(3-piperidin-1-ylsulfonylphenyl)-3H-benzimidazol-4-ol Chemical compound ClC1=CC=C(C2=C1N=C(N2)C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1)O BCKFSWAOFTYFDC-UHFFFAOYSA-N 0.000 claims description 6
- AWIXPFDHIMNZMQ-UHFFFAOYSA-N 9-chloro-3-piperidin-1-ylsulfonyl-11aH-benzo[b][1,4]benzoxazepin-1-one Chemical compound ClC1=CC2=C(C=NC=3C(O2)C(C=C(C=3)S(=O)(=O)N2CCCCC2)=O)C=C1 AWIXPFDHIMNZMQ-UHFFFAOYSA-N 0.000 claims description 6
- MDORFSHEZRYGIY-UHFFFAOYSA-N N-(2-aminoethyl)-3-(5-chloro-1,3-benzoxazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(O1)C=CC(Cl)=C2 MDORFSHEZRYGIY-UHFFFAOYSA-N 0.000 claims description 6
- SKNHCWJVEVFGPD-UHFFFAOYSA-N N-(3-aminopropyl)-3-(1,3-benzothiazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1SC2=C(N=1)C=CC=C2)C1CCCCC1 SKNHCWJVEVFGPD-UHFFFAOYSA-N 0.000 claims description 6
- VQVRPTDMHPGHAT-UHFFFAOYSA-N N-(3-aminopropyl)-3-(1,3-benzoxazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1OC2=C(N=1)C=CC=C2)C1CCCCC1 VQVRPTDMHPGHAT-UHFFFAOYSA-N 0.000 claims description 6
- WZAVNKTUJWXJRP-UHFFFAOYSA-N N-(3-aminopropyl)-3-(1H-benzimidazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(N1)C=CC=C2)C1CCCCC1 WZAVNKTUJWXJRP-UHFFFAOYSA-N 0.000 claims description 6
- ZJLUMTQLKMGGTD-UHFFFAOYSA-N N-(3-aminopropyl)-3-(5-chloro-1,3-benzoxazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1OC2=C(N=1)C=C(C=C2)Cl)C1CCCCC1 ZJLUMTQLKMGGTD-UHFFFAOYSA-N 0.000 claims description 6
- YQLKSGYGOUHIBS-UHFFFAOYSA-N N-(3-aminopropyl)-N-cyclohexyl-3-(5,6-dichloro-1,3-benzoxazol-2-yl)benzenesulfonamide Chemical compound NCCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(O1)C=C(Cl)C(Cl)=C2 YQLKSGYGOUHIBS-UHFFFAOYSA-N 0.000 claims description 6
- XBPKPFRJVBGDIB-UHFFFAOYSA-N N-(3-aminopropyl)-N-cyclohexyl-3-(7-hydroxy-1,3-benzoxazol-2-yl)benzenesulfonamide Chemical compound NCCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NC2=C(O1)C(O)=CC=C2 XBPKPFRJVBGDIB-UHFFFAOYSA-N 0.000 claims description 6
- JYNGSLZZBQVTTA-UHFFFAOYSA-N N-(3-aminopropyl)-N-cyclohexyl-3-(7-methoxy-1,3-benzoxazol-2-yl)benzenesulfonamide Chemical compound COC1=CC=CC2=C1OC(=N2)C1=CC=CC(=C1)S(=O)(=O)N(CCCN)C1CCCCC1 JYNGSLZZBQVTTA-UHFFFAOYSA-N 0.000 claims description 6
- XQOVKULQDAYXSB-UHFFFAOYSA-N N-(3-aminopropyl)-N-cyclohexyl-3-([1,3]thiazolo[4,5-c]pyridin-2-yl)benzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1SC2=C(C=NC=C2)N=1)C1CCCCC1 XQOVKULQDAYXSB-UHFFFAOYSA-N 0.000 claims description 6
- VGJCGHLBTFIAHQ-UHFFFAOYSA-N N-(3-aminopropyl)-N-cyclohexyl-3-([1,3]thiazolo[5,4-b]pyridin-2-yl)benzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1SC2=NC=CC=C2N=1)C1CCCCC1 VGJCGHLBTFIAHQ-UHFFFAOYSA-N 0.000 claims description 6
- XSBODKWMBFFHRA-UHFFFAOYSA-N N-(3-piperidin-1-ylsulfonylphenyl)-1H-indazol-3-amine Chemical compound N1(CCCCC1)S(=O)(=O)C=1C=C(C=CC=1)NC1=NNC2=CC=CC=C12 XSBODKWMBFFHRA-UHFFFAOYSA-N 0.000 claims description 6
- ZYWQEYDMKGSLNI-UHFFFAOYSA-N N-(4-aminobutyl)-3-(5-chloro-1,3-benzoxazol-2-yl)-N-cyclohexylbenzenesulfonamide Chemical compound NCCCCN(S(=O)(=O)C1=CC(=CC=C1)C=1OC2=C(N=1)C=C(C=C2)Cl)C1CCCCC1 ZYWQEYDMKGSLNI-UHFFFAOYSA-N 0.000 claims description 6
- PSAYXBKQGPVIKZ-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(2,3-dihydroindol-1-ylsulfonyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCC2=CC=CC=C12)=O)O PSAYXBKQGPVIKZ-UHFFFAOYSA-N 0.000 claims description 6
- VCHFMWIFHZYNJL-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethylsulfamoyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(NCCO)(=O)=O)=O)O VCHFMWIFHZYNJL-UHFFFAOYSA-N 0.000 claims description 6
- ODFNTSAXCLYUMC-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(2-phenylethylsulfamoyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(NCCC1=CC=CC=C1)(=O)=O)=O)O ODFNTSAXCLYUMC-UHFFFAOYSA-N 0.000 claims description 6
- WKOKQTGBNCDUFW-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(4-hydroxybutylsulfamoyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(NCCCCO)(=O)=O)=O)O WKOKQTGBNCDUFW-UHFFFAOYSA-N 0.000 claims description 6
- SJSJAUZZQKWXCO-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(4-methylpiperazin-1-yl)sulfonylbenzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C)=O)O SJSJAUZZQKWXCO-UHFFFAOYSA-N 0.000 claims description 6
- CPUUQWUOEFRQFU-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(4-phenylbutylsulfamoyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(NCCCCC1=CC=CC=C1)(=O)=O)=O)O CPUUQWUOEFRQFU-UHFFFAOYSA-N 0.000 claims description 6
- SWHYSVGDGMKLDY-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(4-phenylpiperazin-1-yl)sulfonylbenzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C1=CC=CC=C1)=O)O SWHYSVGDGMKLDY-UHFFFAOYSA-N 0.000 claims description 6
- JHQTWVLMLXSFAC-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(4-pyrimidin-2-ylpiperazin-1-yl)sulfonylbenzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C1=NC=CC=N1)=O)O JHQTWVLMLXSFAC-UHFFFAOYSA-N 0.000 claims description 6
- UKBQJWGCMHJUNP-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(cyclohexylsulfamoyl)-4-methylbenzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=C(C=C1)C)S(NC1CCCCC1)(=O)=O)=O)O UKBQJWGCMHJUNP-UHFFFAOYSA-N 0.000 claims description 6
- JQKKPOQUCBUVLT-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(cyclohexylsulfamoyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(NC1CCCCC1)(=O)=O)=O)O JQKKPOQUCBUVLT-UHFFFAOYSA-N 0.000 claims description 6
- ROYDSOGSKVIXLQ-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cyclohexyl(3-phenylpropyl)sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(CCCC1=CC=CC=C1)C1CCCCC1)(=O)=O)=O)O ROYDSOGSKVIXLQ-UHFFFAOYSA-N 0.000 claims description 6
- LNXNOLHQOIRQAJ-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cyclohexyl(5-phenylpentyl)sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(CCCCCC1=CC=CC=C1)C1CCCCC1)(=O)=O)=O)O LNXNOLHQOIRQAJ-UHFFFAOYSA-N 0.000 claims description 6
- KBOSONRAZKXKLK-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cyclohexyl-[3-(dimethylamino)propyl]sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(CCCN(C)C)C1CCCCC1)(=O)=O)=O)O KBOSONRAZKXKLK-UHFFFAOYSA-N 0.000 claims description 6
- MSYGVBVYHRTLNA-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cyclopentyl(methyl)sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(C)C1CCCC1)(=O)=O)=O)O MSYGVBVYHRTLNA-UHFFFAOYSA-N 0.000 claims description 6
- MLQRPLLANXCIDR-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)-3-(dimethylsulfamoyl)benzamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C(=O)NC=2C(=CC=C(Cl)C=2)O)=C1 MLQRPLLANXCIDR-UHFFFAOYSA-N 0.000 claims description 6
- FEQDTMZRXYQMKY-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)-3-[cyclohexyl(methyl)sulfamoyl]benzamide Chemical compound C=1C=CC(C(=O)NC=2C(=CC=C(Cl)C=2)O)=CC=1S(=O)(=O)N(C)C1CCCCC1 FEQDTMZRXYQMKY-UHFFFAOYSA-N 0.000 claims description 6
- ARRZHUJAOCFWDX-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)-3-pyrrolidin-1-ylsulfonylbenzamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCCC2)=C1 ARRZHUJAOCFWDX-UHFFFAOYSA-N 0.000 claims description 6
- JNSIZFZAZJGPHD-UHFFFAOYSA-N tert-butyl 2-[[3-[(5-chloro-2-hydroxyphenyl)carbamoyl]phenyl]sulfonyl-cyclohexylamino]acetate Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C=1C=C(C=CC=1)S(=O)(=O)N(CC(=O)OC(C)(C)C)C1CCCCC1)O JNSIZFZAZJGPHD-UHFFFAOYSA-N 0.000 claims description 6
- NNQFZEWDOULIIG-UHFFFAOYSA-N 4-chloro-2-[4-(3-piperidin-1-ylsulfonylphenyl)triazol-1-yl]phenol Chemical compound ClC1=CC(=C(C=C1)O)N1N=NC(=C1)C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 NNQFZEWDOULIIG-UHFFFAOYSA-N 0.000 claims description 4
- PMEZRZVPQLHXER-UHFFFAOYSA-N [4-chloro-2-[(3-piperidin-1-ylsulfonylbenzoyl)amino]phenyl] dihydrogen phosphate Chemical compound P(=O)(OC1=C(C=C(C=C1)Cl)NC(C1=CC(=CC=C1)S(=O)(=O)N1CCCCC1)=O)(O)O PMEZRZVPQLHXER-UHFFFAOYSA-N 0.000 claims description 4
- JOHAHXYVLYENDN-UHFFFAOYSA-N N-(3-aminopropyl)-3-[5-(5-chloro-2-hydroxyphenyl)-1H-1,2,4-triazol-3-yl]-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(C1CCCCC1)S(=O)(=O)C1=CC(=CC=C1)C1=NNC(=N1)C1=C(O)C=CC(Cl)=C1 JOHAHXYVLYENDN-UHFFFAOYSA-N 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- SUZXWXGJCOCMHU-UHFFFAOYSA-N n-sulfonylbenzamide Chemical compound O=S(=O)=NC(=O)C1=CC=CC=C1 SUZXWXGJCOCMHU-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- LTPNHQSIGLUUNA-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-[cyclohexyl(3-hydroxypropyl)sulfamoyl]benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)S(N(CCCO)C1CCCCC1)(=O)=O)=O)O LTPNHQSIGLUUNA-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- NZUANQHZMJYUJR-UHFFFAOYSA-N n-(5-chloro-2-hydroxyphenyl)-3-morpholin-4-ylsulfonylbenzamide Chemical compound OC1=CC=C(Cl)C=C1NC(=O)C1=CC=CC(S(=O)(=O)N2CCOCC2)=C1 NZUANQHZMJYUJR-UHFFFAOYSA-N 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000014347 soups Nutrition 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MSWQVDKEJVPJII-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N,N-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC(=CC=C1)S(=O)(=O)N(CCCN)C1CCCCC1 MSWQVDKEJVPJII-UHFFFAOYSA-N 0.000 description 2
- LARDFKADGAFIQJ-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-(3-chlorophenyl)benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=CC(=CC=C2)Cl)C=CC=1)C1CCCCC1 LARDFKADGAFIQJ-UHFFFAOYSA-N 0.000 description 2
- ZHDRAGQQBWBJHV-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-methylbenzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC)C=CC=1)C1CCCCC1 ZHDRAGQQBWBJHV-UHFFFAOYSA-N 0.000 description 2
- IBELRIBCQFEUGB-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]-N-phenylbenzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1)C1CCCCC1 IBELRIBCQFEUGB-UHFFFAOYSA-N 0.000 description 2
- IKWYLXYZWHENBH-UHFFFAOYSA-N 3-[3-aminopropyl(cyclohexyl)sulfamoyl]benzamide Chemical compound NCCCN(S(=O)(=O)C=1C=C(C(=O)N)C=CC=1)C1CCCCC1 IKWYLXYZWHENBH-UHFFFAOYSA-N 0.000 description 2
- NURLTRBBGCQZAC-UHFFFAOYSA-N 4-chloro-2-[(3-piperidin-1-ylsulfonylphenyl)methylamino]phenol Chemical compound ClC1=CC(=C(C=C1)O)NCC1=CC(=CC=C1)S(=O)(=O)N1CCCCC1 NURLTRBBGCQZAC-UHFFFAOYSA-N 0.000 description 2
- PMTAVDSJNVOCLC-UHFFFAOYSA-N N'-[(3-bromophenyl)methyl]-N'-cyclohexylpropane-1,3-diamine Chemical compound BrC=1C=C(C=CC=1)CN(CCCN)C1CCCCC1 PMTAVDSJNVOCLC-UHFFFAOYSA-N 0.000 description 2
- SOHFHYDQDLILCG-UHFFFAOYSA-N N-(3-aminopropyl)-2-bromo-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=C(C=CC=C1)Br)C1CCCCC1 SOHFHYDQDLILCG-UHFFFAOYSA-N 0.000 description 2
- NKYYCSXUGIRGKU-UHFFFAOYSA-N N-(3-aminopropyl)-3-bromo-N-cyclohexylbenzamide Chemical compound NCCCN(C(C1=CC(=CC=C1)Br)=O)C1CCCCC1 NKYYCSXUGIRGKU-UHFFFAOYSA-N 0.000 description 2
- SGWMKQCKRHHQEC-UHFFFAOYSA-N N-(3-aminopropyl)-3-bromo-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC(=CC=C1)Br)C1CCCCC1 SGWMKQCKRHHQEC-UHFFFAOYSA-N 0.000 description 2
- RLKUBVLIORFAOY-UHFFFAOYSA-N N-(3-aminopropyl)-4-bromo-N-cyclohexylbenzenesulfonamide Chemical compound NCCCN(S(=O)(=O)C1=CC=C(C=C1)Br)C1CCCCC1 RLKUBVLIORFAOY-UHFFFAOYSA-N 0.000 description 2
- MUPNHVLFAMGLNO-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-1,1-dioxo-2,3-dihydro-1,2-benzothiazole-6-carboxamide Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C1=CC2=C(CNS2(=O)=O)C=C1)O MUPNHVLFAMGLNO-UHFFFAOYSA-N 0.000 description 2
- MTTJKOSTXKZTBH-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-2-(cyclohexylsulfonylamino)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=C(C=CC=C1)NS(=O)(=O)C1CCCCC1)=O)O MTTJKOSTXKZTBH-UHFFFAOYSA-N 0.000 description 2
- SIUHBHBRPNUHQE-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(cyclohexylsulfonylamino)-5-methoxybenzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC(=C1)OC)NS(=O)(=O)C1CCCCC1)=O)O SIUHBHBRPNUHQE-UHFFFAOYSA-N 0.000 description 2
- WZBVMOWDVQTUNF-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(cyclohexylsulfonylamino)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)NS(=O)(=O)C1CCCCC1)=O)O WZBVMOWDVQTUNF-UHFFFAOYSA-N 0.000 description 2
- XOLBCLIAGGCTLN-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-3-(piperidine-1-carbonyl)benzamide Chemical compound ClC=1C=CC(=C(C=1)NC(C1=CC(=CC=C1)C(=O)N1CCCCC1)=O)O XOLBCLIAGGCTLN-UHFFFAOYSA-N 0.000 description 2
- WMIBPYQTOKMZFT-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-5-(cyclohexylsulfonylamino)pyridine-3-carboxamide Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C=1C=NC=C(C=1)NS(=O)(=O)C1CCCCC1)O WMIBPYQTOKMZFT-UHFFFAOYSA-N 0.000 description 2
- GDFMIMXVGCCEBY-UHFFFAOYSA-N N-(5-chloro-2-hydroxyphenyl)-6-(cyclohexylsulfonylamino)pyridine-2-carboxamide Chemical compound ClC=1C=CC(=C(C=1)NC(=O)C1=NC(=CC=C1)NS(=O)(=O)C1CCCCC1)O GDFMIMXVGCCEBY-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- ASLJWJUOSIJRCV-UHFFFAOYSA-N n-(3-aminopropyl)-n-cyclohexylbenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CCCN)C1CCCCC1 ASLJWJUOSIJRCV-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 0 **(C*CC1)CN1S(=O)=O Chemical compound **(C*CC1)CN1S(=O)=O 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019205835A JP6967054B2 (ja) | 2014-07-31 | 2019-11-13 | Ｆｌｔ３レセプターアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306225.5 | 2014-07-31 | ||
| EP14306225 | 2014-07-31 | ||
| PCT/EP2015/067510 WO2016016370A1 (en) | 2014-07-31 | 2015-07-30 | Flt3 receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205835A Division JP6967054B2 (ja) | 2014-07-31 | 2019-11-13 | Ｆｌｔ３レセプターアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523972A JP2017523972A (ja) | 2017-08-24 |
| JP2017523972A5 true JP2017523972A5 (enExample) | 2018-08-30 |
Family
ID=51298678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504815A Pending JP2017523972A (ja) | 2014-07-31 | 2015-07-30 | Ｆｌｔ３レセプターアンタゴニスト |
| JP2019205835A Active JP6967054B2 (ja) | 2014-07-31 | 2019-11-13 | Ｆｌｔ３レセプターアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205835A Active JP6967054B2 (ja) | 2014-07-31 | 2019-11-13 | Ｆｌｔ３レセプターアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10065937B2 (enExample) |
| EP (1) | EP3174859B1 (enExample) |
| JP (2) | JP2017523972A (enExample) |
| CN (1) | CN107001283B (enExample) |
| AU (1) | AU2015295288B2 (enExample) |
| BR (1) | BR112017002001B1 (enExample) |
| CA (1) | CA2956417C (enExample) |
| RU (1) | RU2710928C2 (enExample) |
| WO (1) | WO2016016370A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970104B1 (en) | 2013-03-14 | 2019-04-24 | Zeno Royalties & Milestones, LLC | Bicyclic analgesic compounds |
| CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| CN113336653A (zh) | 2014-03-07 | 2021-09-03 | 里科瑞尔姆Ip控股有限责任公司 | 螺桨烷衍生物及合成 |
| EP3193855B1 (en) | 2014-09-17 | 2021-05-19 | Recurium IP Holdings, LLC | Bicyclic compounds |
| US9765050B2 (en) | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
| WO2016161268A1 (en) * | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
| WO2017160926A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| EP3254698A1 (en) * | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| KR20190027814A (ko) | 2016-06-10 | 2019-03-15 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| ES2877763T3 (es) | 2016-09-20 | 2021-11-17 | Glaxosmithkline Ip No 2 Ltd | Antagonistas del trpv4 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| US11242327B2 (en) | 2017-05-15 | 2022-02-08 | Recurium Ip Holdings, Llc | Analgesic compounds |
| US20200171022A1 (en) * | 2017-05-17 | 2020-06-04 | Inserm (Institut National De La Santé Et Da La Recherche Médicale) | Flt3 inhibitors for improving pain treatments by opioids |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| CN108383801B (zh) * | 2018-01-25 | 2023-05-26 | 于磊 | Sglt2蛋白的抑制剂以及应用 |
| CN111868051B (zh) * | 2018-03-23 | 2024-04-09 | 斯泰普制药股份公司 | 作为ctps1抑制剂的氨基嘧啶衍生物 |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN110833554B (zh) * | 2018-08-15 | 2022-03-08 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗自身免疫性甲状腺疾病的用途 |
| CN110833551B (zh) * | 2018-08-15 | 2023-03-24 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗急性胰腺炎的用途 |
| CN110833555B (zh) * | 2018-08-15 | 2023-03-24 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗溃疡性结肠炎的用途 |
| US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN109799354A (zh) * | 2019-02-15 | 2019-05-24 | 浠思（上海）生物技术有限公司 | 利用Tag-lite结合分析实验技术筛选腺苷A2A受体配体的方法 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| US20240124466A1 (en) * | 2020-12-11 | 2024-04-18 | Vova Ida Therapeutics, Inc. | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
| CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
| EP4353712A1 (en) | 2022-10-11 | 2024-04-17 | Biodol Therapeutics | New n-heteroarylbenzamides derivatives as flt3 inhibitors |
| WO2024211444A2 (en) * | 2023-04-03 | 2024-10-10 | Duke University | Antibiotics comprising lpxh-targeting compounds and methods of making and using the same |
| TW202506660A (zh) * | 2023-04-27 | 2025-02-16 | 美商塞普特納公司 | Mrgprx2拮抗劑及其使用方法 |
| CN118255698A (zh) * | 2024-03-26 | 2024-06-28 | 海南大学 | 一种磺酰胺类化合物及其制备方法与用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO2002032861A2 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| TWI302836B (en) | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| MXPA04006271A (es) | 2001-12-27 | 2004-10-04 | Theravance Inc | Derivados de indolinona utiles como inhibidores de la proteina cinasa. |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US20080207617A1 (en) | 2002-10-29 | 2008-08-28 | Kirin Beer Kabushiki Kaisha | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same |
| US7838527B2 (en) | 2002-11-13 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| AU2003297160A1 (en) | 2002-12-18 | 2004-07-22 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| EP1951234A2 (en) | 2005-10-18 | 2008-08-06 | Janssen Pharmaceutica N.V. | Method of inhibiting flt3 kinase |
| EP2001892B1 (en) | 2006-03-17 | 2013-04-24 | Ambit Biosciences Corporation | Imidazolothiazole compounds for the treatment of proliferative diseases |
| JP5645667B2 (ja) | 2007-11-08 | 2014-12-24 | アムビト ビオスシエンセス コルポラチオン | 増殖性疾患を治療するための、Ｎ−（５−ｔｅｒｔ−ブチル−イソキサゾール−３−イル）−Ｎ’−｛４−［７−（２−モルホリン−４−イル−エトキシ）イミダゾ［２，ｌ−ｂ］［ｌ，３］ベンゾチアゾール−２−イル］フェニル｝尿素の投与方法 |
| EP2068152A1 (en) | 2007-12-06 | 2009-06-10 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | c-Kit as a novel target for the treatment of pain |
| US8436171B2 (en) * | 2008-02-01 | 2013-05-07 | Akinion Pharmaceuticals Ab | Amino substituted pyrazines as inhibitors or protein kinases |
| JP5501226B2 (ja) * | 2008-04-24 | 2014-05-21 | Ｍｓｄ株式会社 | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| EP2521782B1 (en) * | 2010-01-05 | 2019-04-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
| US9266838B2 (en) * | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| MX373711B (es) * | 2012-08-28 | 2020-05-08 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. |
-
2015
- 2015-07-30 WO PCT/EP2015/067510 patent/WO2016016370A1/en not_active Ceased
- 2015-07-30 AU AU2015295288A patent/AU2015295288B2/en active Active
- 2015-07-30 RU RU2017102713A patent/RU2710928C2/ru active
- 2015-07-30 JP JP2017504815A patent/JP2017523972A/ja active Pending
- 2015-07-30 CA CA2956417A patent/CA2956417C/en active Active
- 2015-07-30 BR BR112017002001-7A patent/BR112017002001B1/pt active IP Right Grant
- 2015-07-30 US US15/500,174 patent/US10065937B2/en active Active
- 2015-07-30 EP EP15744234.4A patent/EP3174859B1/en active Active
- 2015-07-30 CN CN201580052077.6A patent/CN107001283B/zh active Active
-
2019
- 2019-11-13 JP JP2019205835A patent/JP6967054B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523972A5 (enExample) | ||
| RU2017102713A (ru) | Антагонисты рецептора flt3 | |
| DK2451794T3 (en) | 1,2,4-thiazolidin-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | |
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| JP2008540574A5 (enExample) | ||
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| JP5674828B2 (ja) | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 | |
| JP2009535307A5 (enExample) | ||
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| RU2501791C2 (ru) | Производное триазола или его соль | |
| JP2004517080A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2006077019A5 (enExample) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2008524246A5 (enExample) | ||
| JP2008516986A5 (enExample) | ||
| JP2005517006A5 (enExample) | ||
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| JP2009529059A5 (enExample) | ||
| CA2494832A1 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
| JPWO2010007966A1 (ja) | アゾール化合物 | |
| RU2013132930A (ru) | Производное пиразола | |
| JP2010536821A5 (enExample) | ||
| CA2618511A1 (en) | Novel benzothiazolone derivatives |